FDA questions Amgen drug for prostate cancer

February 6, 2012 8:45:11 AM PST
Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.